Screening for cancer: future potential

Hakama M. Trends in the incidence of cervical cancer in the Nordic countries. In Magnus K, ed. Trends in Cancer Incidence: Causes and Practical Implications. Washington, U.S.A., Hemisphere Publishing Corporation, 1982, 279–292. Läärä E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1987, i (30 May), 1247–1249. Sasieni, 1995, Accelerated decline in cervical cancer mortality in England and Wales, Lancet, 346, 1566, 10.1016/S0140-6736(95)92099-4 Banda-Gamboa, 1998, Automation in cervical cytology: an overview, Anal. Cell. Pathol., 4, 25 Williams, 1998, Improved cervical smear assessment using antibodies against proteins that regulate DNA replication, Proc. Natl. Acad. Sci., 95, 14932, 10.1073/pnas.95.25.14932 Reid R, Greenberg MD, Lorincz A, et al. Should cervical cytologic testing be augmented by cervicography or human papillomavirus deoxyribonucleic acid detection? Am J Obstet Gynecol 1991, 164, 1461–1469; 1469–1471. Cuzick, 1995, Human papillomavirus testing in primary cervical screening, Lancet, 345, 1533, 10.1016/S0140-6736(95)91086-7 Schneider, 1996, Screening for cervical intraepithelial neoplasia grade 2/3: validity of cytologic study, cervicography, and human papillomavirus detection, Am. J. Obstet. Gynecol., 174, 1534, 10.1016/S0002-9378(96)70602-6 Ratnam S, Prafull G, Franco E, Ferenczy A. Utility of HPV testing in combination with Papanicolaou smear in primary cervical screening. 17th International Papillomavirus Conference, January 9–15 1999, Charleston, South Carolina, U.S.A. Cuzick, 1992, Human papillomavirus type IL DNA in cervical smears as a predictor of high grade cervical intraepithelial neoplasia, Lancet, 339, 959, 10.1016/0140-6736(92)91532-D Elfgren, 1996, Conization for cervical intraepithelial neoplasia is followed by disappearance of human papillomavirus deoxyribonucleic acid and a decline in serum and cervical mucus antibodies against human papillomavirus antigens, Am. J. Obstet. Gynecol., 174, 937, 10.1016/S0002-9378(96)70330-7 Bollen, 1996, Human papillomavirus DNA after treatment of cervical dysplasia: low prevalence in normal cytologic smears, Cancer, 77, 2538, 10.1002/(SICI)1097-0142(19960615)77:12<2538::AID-CNCR17>3.0.CO;2-T Nyström, 1993, Breast cancer screening with mammography: overview of Swedish randomised trials, Lancet, 341, 973, 10.1016/0140-6736(93)91067-V Falun Organising Committee. Breast cancer screening with mammography in women aged 40–49 years. Int J Cancer 1996, 68, 693–699. Bjurstam, 1997, The Gothenburg Breast Screening Trial, Cancer, 80, 2091, 10.1002/(SICI)1097-0142(19971201)80:11<2091::AID-CNCR8>3.0.CO;2-# Cuzick, 1998, Electropotential measurements as a new modality for breast cancer diagnosis: results from a multicentre trial, Lancet, 352, 359, 10.1016/S0140-6736(97)10002-2 Morimoto, 1990, Measurement of the electrical bio-impedance of breast tumors, Eur. Surg. Res., 22, 86, 10.1159/000129087 Simpson, 1993, The luteal heat cycle of the breast in health, Breast Cancer Res. Treat., 27, 239, 10.1007/BF00665693 Coppleson, 1994, An electronic approach to the detection of pre-cancer and cancer of the uterine cervix: a preliminary evaluation of Polarprobe, Int. J. Gynecol. Cancer., 4, 79, 10.1046/j.1525-1438.1994.04020079.x Mandel, 1993, Reducing mortality from colorectal cancer by screening for fecal occult blood, N. Engl. J. Med., 328, 1365, 10.1056/NEJM199305133281901 Hardcastle, 1996, Randomised controlled trial of faecal-occult-blood screening for colorectal cancer, Lancet, 348, 1472, 10.1016/S0140-6736(96)03386-7 Kronberg, 1996, Randomised study of screening for colorectal cancer with faecal-occult-blood test, Lancet, 348, 1467, 10.1016/S0140-6736(96)03430-7 Faivre, 1999, Faecal occult blood screening and reduction of colorectal cancer mortality: a case–control study, Br. J. Cancer, 79, 680, 10.1038/sj.bjc.6690107 Ahlquist, 1993, Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests, JAMA, 269, 1262, 10.1001/jama.1993.03500100060028 St John, 1993, Evaluation of new occult blood tests for detection of colorectal neoplasia, Gastroenterology, 104, 1661, 10.1016/0016-5085(93)90643-Q Morson, 1976, Genesis of colorectal cancer, Gastroenterology, 5, 505 Selby, 1992, A case–control study of screening sigmoidoscopy and mortality from colorectal cancer, N. Engl. J. Med., 326, 653, 10.1056/NEJM199203053261001 Newcomb, 1992, Screening sigmoidoscopy and colorectal cancer morality, J. Natl. Clin. Inst., 84, 1572, 10.1093/jnci/84.20.1572 Müller, 1983, Protection by endoscopy against death from colorectal cancer: a case–control study among veterans, Arch. Intern. Med., 155, 1741, 10.1001/archinte.1995.00430160065007 Atkin, 1993, Prevention of colorectal cancer by once-only sigmoidoscopy, Lancet, 341, 736, 10.1016/0140-6736(93)90499-7 Breslow, 1977, Latent carcinoma of prostate at autopsy in seven areas, Int. J. Cancer, 20, 680, 10.1002/ijc.2910200506 Bentvelsen, 1993, Modalities available for screening for prostate cancer, Eur. J. Cancer, 29A, 804, 10.1016/S0959-8049(05)80413-7 Campbell, 1989, Transabdominal ultrasound screening for early ovarian cancer, Br. Med. J., 299, 1363, 10.1136/bmj.299.6712.1363 Bourne, 1993, Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging, Br. Med. J., 306, 1025, 10.1136/bmj.306.6884.1025 Jacobs, 1993, Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography, Br. Med. J., 306, 1030, 10.1136/bmj.306.6884.1030 Bourne, 1994, The potential role of serum CA 125 in an ultrasound-based screening program for familial ovarian cancer, Gynecologic. Oncol, 52, 379, 10.1006/gyno.1994.1065 Prorok PC, Byar DP, Smart CR, Baker SG, Connor RJ. Evaluation of screening for prostate, lung, and colorectal cancers: the PLC Trial. In Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge University Press, New York, 1976, 300–320. Hisamichi S, Fukao A, Sugawara N, et al. Evaluation of mass screening programme for stomach cancer in Japan. In Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge University Press, New York, 1991, 357–370. De Koster, 1993, Gastric screening prospects, Eur. J. Cancer Prev., 2, 263, 10.1097/00008469-199305000-00013 Sun T, Yu H, Hsia C, Wang N, Huang X. Evaluation of sero-survey trials for the early detection of hepatocellular carcinoma in area of high prevalence. In Chamberlain J, Miller AB. Screening for Gastrointestinal Cancer. Bern, Hans Huber, 1988, 81–86. Shen, 1993, Cytologic screening for esophageal cancer: results from 12,877 subjects from a high-risk population in China, Int. J. Cancer, 54, 185, 10.1002/ijc.2910540204 Chen, 1989, Antibody to Epstein–Barr virus-specific Dnase as a marker for field survey of patients with nasopharyngeal carcinoma in Taiwan, J. Med. Virol., 27, 269, 10.1002/jmv.1890270403 Sawada T, Matsumura T, Matsuda Y, Kawakatsu H. Neuroblastoma: studies in Japan. In Miller AB, Chamberlain J, Day NE, Hakama M, Prorok PC, eds. Cancer Screening. Cambridge University Press, New York, 1991, 325–336. Sawada, 1992, Past and future of neuroblastoma screening in Japan, Am. J. Pediatr. Hematol. Oncol., 14, 320, 10.1097/00043426-199211000-00007 Murphy, 1991, Do children benefit from mass screening for neuroblastoma?, Lancet, 337, 344, 10.1016/0140-6736(91)90957-Q Womack SD, Chirenje ZM, Blumenthal PD, et al. Evaluation of Hybrid Capture II, probe-B assay in cervical cancer screening of women in Zimbabwe, Africa. In Womack SD, Chirenje ZM, Blumenthal PD, Gaffikin L, McGrath J, Chipato T, Ngwalle E, Shah KV, eds. 17th International Papillomavirus Conference. Charleston, South Carolina, U.S.A., 1999, 285. Gurley M, Carter CD, Bounassif S, Laverty CRA, Tabrizi SN, Garland SM. Does HPV status have a role in the management of women with abnormal cervical cytology? In Gurley M, Carter CD, Bounassif S, Laverty CRA, Tabrizi SN, Garland SM, eds. 17th International Papillomavirus Conference. Charleston, South Carolina, U.S.A., 1999, 288. Clavel C, Masure M, Bory J-P, et al. Human papillomavirus detection by the hybrid capture II assay is a sensitive test to detect in routine high grade cervcial lesion. In Clavel C, Masure M, Bory J-P, et al., eds. 17th International Papillomavirus Conference. Charleston, South Carolina, U.S.A., 1999, 170. Cuzick J, Beverley E, Ho L, et al. HPV testing in primary screening of older women. In Cuzick J, Beverley E, Ho L, et al., eds. 17th International Papillomavirus Conference. Charleston, South Carolina, U.S.A., 1999, 98. Gilbertsen, 1978, The prevention of invasive cancer of the rectum, Cancer, 41, 1137, 10.1002/1097-0142(197803)41:3<1137::AID-CNCR2820410350>3.0.CO;2-G Friedman, 1986, Multiphasic health check-up evaluation: a 16-year follow-up, J. Chron. Dis., 39, 453, 10.1016/0021-9681(86)90112-8 Atkin, 1992, Long-term risk of colorectal cancer after excision of rectosigmoid adenomas, N. Engl. J. Med., 326, 658, 10.1056/NEJM199203053261002 Winawer, 1993, Prevention of colorectal cancer by colonoscopic polypectomy, N. Engl. J. Med., 329, 1977, 10.1056/NEJM199312303292701